Rosty Raykov Sells 2,431 Shares of Fennec Pharmaceuticals Inc (NASDAQ:FENC) Stock

Fennec Pharmaceuticals Inc (NASDAQ:FENC) CEO Rosty Raykov sold 2,431 shares of the stock in a transaction on Tuesday, July 2nd. The shares were sold at an average price of $6.13, for a total value of $14,902.03. Following the sale, the chief executive officer now owns 187,471 shares in the company, valued at approximately $1,149,197.23. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Rosty Raykov also recently made the following trade(s):

• On Monday, June 3rd, Rosty Raykov sold 2,431 shares of Fennec Pharmaceuticals stock. The shares were sold at an average price of $6.76, for a total value of $16,433.56.
• On Wednesday, May 1st, Rosty Raykov sold 2,431 shares of Fennec Pharmaceuticals stock. The shares were sold at an average price of $9.11, for a total value of $22,146.41.
• On Friday, April 5th, Rosty Raykov sold 44,300 shares of Fennec Pharmaceuticals stock. The shares were sold at an average price of $10.75, for a total value of $476,225.00.
• On Wednesday, April 3rd, Rosty Raykov sold 40,584 shares of Fennec Pharmaceuticals stock. The shares were sold at an average price of $10.78, for a total value of $437,495.52.

Fennec Pharmaceuticals Trading Down 3.8 %

Shares of FENC stock traded down $0.24 during mid-day trading on Tuesday, hitting $6.03. 56,012 shares of the company’s stock were exchanged, compared to its average volume of 133,329. Fennec Pharmaceuticals Inc has a fifty-two week low of $5.99 and a fifty-two week high of $11.92. The stock has a 50-day simple moving average of $7.53 and a two-hundred day simple moving average of $9.27. The company has a quick ratio of 6.72, a current ratio of 6.93 and a debt-to-equity ratio of 9.86. The stock has a market cap of $164.74 million, a price-to-earnings ratio of 201.00 and a beta of 0.29.

Fennec Pharmaceuticals (NASDAQ:FENC) last posted its quarterly earnings data on Tuesday, May 14th. The company reported $0.41 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.49 by ($0.08). Fennec Pharmaceuticals had a negative return on equity of 39.41% and a net margin of 6.33%. The business had revenue of $25.38 million for the quarter, compared to analyst estimates of $10.46 million. During the same quarter last year, the business earned ($0.23) EPS. Equities analysts expect that Fennec Pharmaceuticals Inc will post 0.36 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in FENC. Tower Research Capital LLC TRC boosted its holdings in Fennec Pharmaceuticals by 107.3% in the fourth quarter. Tower Research Capital LLC TRC now owns 3,048 shares of the company’s stock valued at $34,000 after acquiring an additional 1,578 shares during the last quarter. Jump Financial LLC acquired a new position in Fennec Pharmaceuticals in the fourth quarter valued at $158,000. BNP Paribas Financial Markets boosted its holdings in Fennec Pharmaceuticals by 67.7% in the first quarter. BNP Paribas Financial Markets now owns 32,769 shares of the company’s stock valued at $364,000 after acquiring an additional 13,223 shares during the last quarter. Eudaimonia Advisors LLC boosted its holdings in Fennec Pharmaceuticals by 90.8% in the fourth quarter. Eudaimonia Advisors LLC now owns 32,686 shares of the company’s stock valued at $367,000 after acquiring an additional 15,556 shares during the last quarter. Finally, Russell Investments Group Ltd. boosted its holdings in Fennec Pharmaceuticals by 71,275.0% in the first quarter. Russell Investments Group Ltd. now owns 34,260 shares of the company’s stock valued at $381,000 after acquiring an additional 34,212 shares during the last quarter. Institutional investors and hedge funds own 55.51% of the company’s stock.

Analysts Set New Price Targets

FENC has been the topic of a number of analyst reports. Wedbush reiterated an “outperform” rating and set a $16.00 target price on shares of Fennec Pharmaceuticals in a report on Tuesday, May 14th. Craig Hallum decreased their price objective on Fennec Pharmaceuticals from $20.00 to $17.00 and set a “buy” rating on the stock in a report on Wednesday, May 15th. Finally, HC Wainwright decreased their price objective on Fennec Pharmaceuticals from $18.00 to $15.00 and set a “buy” rating on the stock in a report on Wednesday, May 15th.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.